Trials / Recruiting
RecruitingNCT06530316
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
The Efficacy and Safety of RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer: a Real-world Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 14 Years – 80 Years
- Healthy volunteers
- —
Summary
This study is a multicenter observational study. Patients receive neoadjuvant therapy with RET inhibitors in the real world, and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to determine the efficacy and safety of RET inhibitors for neoadjuvant therapy in locally advanced RET-altered thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RET Inhibitor | RET inhibitors for neoadjuvant treatment |
| PROCEDURE | Surgery | Operable patients receive surgery after neoadjuvant therapy |
Timeline
- Start date
- 2024-07-18
- Primary completion
- 2026-12-31
- Completion
- 2029-12-31
- First posted
- 2024-07-31
- Last updated
- 2024-08-02
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06530316. Inclusion in this directory is not an endorsement.